What does AIM ImmunoTech Inc. do?
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded…
What is AIM ImmunoTech Inc.'s P/E and P/B ratio?
AIM ImmunoTech Inc. has a P/E ratio of -0.1 and a P/B ratio of 3.02.
What is AIM ImmunoTech Inc.'s debt-to-equity ratio?
AIM ImmunoTech Inc. has a debt-to-equity ratio of 0.51.
How much does AIM ImmunoTech Inc. owe compared with what it owns?
AIM ImmunoTech Inc. owes $0.75 for every $1 it owns (balance sheet Mar 2026), which is moderate.
What is AIM ImmunoTech Inc.'s Positivity rank?
AIM ImmunoTech Inc. is ranked #2,442 of 6,774 companies globally and #782 of 4,000 in United States on PositoAI, with a Positivity Score of 21,515.
Does AIM ImmunoTech Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
AIM ImmunoTech Inc. has no active red flags. It has 1 yellow flag (PosiYellow stress signals, 2/10 points): Quarterly report filed late (NT 10-Q).
Where can I read the latest news about AIM ImmunoTech Inc.?
Recent headlines about AIM ImmunoTech Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does AIM ImmunoTech Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of AIM ImmunoTech Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.